-
Tysabri®
Tysabri® (natalizumab) is a monoclonal antibody therapy designed to help patients with relapsing forms of multiple sclerosis (RMS) and certain inflammatory conditions better manage their symptoms and reduce disease activity. At Singlepoint Healthcare, we offer safe, supportive, and personalized settings for Tysabri infusions, ensuring each patient receives the highest standard of care.
How Tysabri® Works
As a monoclonal antibody, Tysabri works by preventing immune cells from entering the brain and spinal cord, helping protect the nervous system from ongoing damage.
Tysabri reduces inflammation, lowers relapse rates, and helps prevent new lesions from forming in the central nervous system. For many patients, this therapy offers improved symptom control, enhanced daily functioning, and a significant reduction in disease progression.
Key Details
Important Information
| Category | Details |
|---|---|
| Conditions It Treats | Crohn’s Disease, Multiple Sclerosis |
| Manufacturer | Biogen |
| Administered by | Infusion |
| Frequency | Monthly |
| Length of Infusion | 60 Minutes |
| FDA Approval(s) | Multiple Sclerosis (MS): Approved on November 23, 2004 Crohn's Disease: Approved on January 14, 2008 |